Merck KGaA, Darmstadt, Germany Finalizes $3.4 Billion Acquisition of SpringWorks Therapeutics
Merck KGaA, Darmstadt, Germany, a global science and technology leader, has announced the completion of its acquisition of SpringWorks Therapeutics, Inc. for an enterprise value of $3.4 billion (approximately €3 billion). The transaction, first announced in April 2025, closed following the receipt of regulatory clearances and the fulfillment of customary closing conditions.
This acquisition marks one of the largest biopharmaceutical deals of the year and represents a major milestone in Merck KGaA, Darmstadt, Germany’s long-term growth strategy in healthcare.
A Transformational Deal for the Healthcare Business
SpringWorks, a biopharmaceutical company headquartered in Stamford, Connecticut, specializes in innovative therapies for rare tumors and diseases with high unmet medical need. Through this acquisition, Merck KGaA, Darmstadt, Germany adds a robust pipeline and two U.S. FDA-approved therapies to its portfolio.
“Today, we officially welcome SpringWorks to Merck KGaA, Darmstadt, Germany. The acquisition of SpringWorks illustrates our decisive portfolio approach to further position Merck KGaA, Darmstadt, Germany as a globally diversified science and technology powerhouse,” said Belén Garijo, Chair of the Executive Board and CEO. “This is the largest acquisition we have made for our Healthcare business sector in nearly 20 years, marking an exciting new chapter for Healthcare.”
Garijo also reaffirmed the company’s ongoing commitment to pursuing strategic mergers and acquisitions across all three of its business sectors, with a particular focus on opportunities in life science, long-term value creation, and financial stability.
Enhancing Access to Innovative Rare Tumor Treatments
SpringWorks brings with it two breakthrough treatments already approved by the U.S. Food and Drug Administration (FDA):
- OGSIVEO® (nirogacestat): The first and only FDA-approved therapy for progressing desmoid tumors in adults requiring systemic treatment. These rare, locally aggressive soft tissue tumors can cause significant morbidity despite being non-metastatic. In June 2025, the European Medicines Agency’s (EMA) CHMP (Committee for Medicinal Products for Human Use) issued a positive opinion recommending nirogacestat for approval in the European Union.
- GOMEKLI® (mirdametinib): Approved by the FDA for adults and children as young as two with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not suitable for surgical resection. The EMA also issued a positive opinion for mirdametinib in May 2025, signaling its likely approval in Europe in the near future.
“This acquisition is a significant step forward in bringing innovation to patients living with rare and often debilitating tumors—many of whom are young and facing a long, uncertain journey with limited treatment options,” said Danny Bar-Zohar, CEO of Healthcare and member of the Executive Board. “By combining our global reach with SpringWorks’ expertise, we are expanding access to life-changing therapies around the world.”
Strategic Fit and Growth Potential
SpringWorks’ portfolio complements Merck KGaA, Darmstadt, Germany’s existing rare tumor strategy. This includes pimicotinib, an investigational treatment for tenosynovial giant cell tumor (TGCT), developed in partnership with Abbisko Therapeutics Co., Ltd. Merck KGaA, Darmstadt, Germany holds global commercialization rights for the drug and is currently preparing regulatory filings.
The combined pipeline positions Merck KGaA, Darmstadt, Germany as a leader in rare tumor therapeutics, addressing multiple underserved patient populations. The company anticipates that the acquisition will start contributing to revenues immediately and become accretive to EPS pre by 2027.
Transition and Integration
With the closing of the deal, SpringWorks’ shares will no longer be publicly traded on Nasdaq, and the company is now a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany. Shareholders of SpringWorks received $47 per share in cash as part of the transaction.
The integration of SpringWorks will focus on accelerating the global availability of its products, leveraging Merck KGaA, Darmstadt, Germany’s commercial infrastructure and scientific capabilities.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck KGaA, Darmstadt, Germany, generated sales of € 21.2 billion in 65 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register online, change your selection or discontinue this service.
